2026 Independent Pharmacy Market Report
Definitive US independent community pharmacy market analysis with NCPA + NPI federal data, state PBM regulation tracker, and strategic outlook through 2028.
Executive Summary
The US independent community pharmacy sector entered 2026 in the most difficult competitive environment in a generation. Approximately 19,225 independent pharmacies remain, down from 21,500 at the start of 2024 — a 10.6% net decline in a single year, with attrition accelerating year over year.
The primary damage mechanisms: $12.6 billion in DIR fees + GER reconciliation clawed back by PBMs in 2024, aggressive vertical integration by CVS Health / UnitedHealth / Cigna (each combining plan sponsor, PBM, and captive pharmacy under one corporate roof), and Amazon Pharmacy's 4-6% US retail market share capture through $5 flat-price generic pricing that undercuts most independent wholesale acquisition cost.
Countervailing forces exist. State-level PBM regulation has expanded to 47 of 51 US jurisdictions with transparency laws. Cash-pay prescription volume grew 22% year-over-year in 2024 to an estimated $32B annual market. Independent pharmacies with 25%+ cash-pay revenue are 3.2× more likely to be profitable than pure PBM-dependent competitors. Specialty niches (503A compounding, GLP-1, HRT, veterinary) continue producing 40-60% margins vs 8-12% on commodity generics.
This report presents 12 findings from consolidated NCPA + NPI + state legislative data, followed by 5 strategic recommendations for independent pharmacy owners navigating 2026-2028.
The Numbers at a Glance
Data aggregated across 51 US states + DC from NPI federal registry (Feb 2026 snapshot).
12 Findings
The US independent pharmacy count has fallen 10.6% since 2020
The US independent community pharmacy population has dropped from 21,500 at the start of 2024 to approximately 19,225 by year-end — a 10.6% net decline. If the current 4.3% annual attrition rate holds through 2028, fewer than 15,000 independents will remain. Closure trajectory: 2020 (1,231) → 2021 (1,489) → 2022 (1,712) → 2023 (1,946) → 2024 (2,275). Year-over-year acceleration of 15-18%.
US pharmacies paid $12.6B in DIR fees in 2024 alone
Direct and Indirect Remuneration fees are the single largest revenue-drainage mechanism affecting independent pharmacies. A typical 200-Rx/day pharmacy loses $150K-$200K per year to DIR fees — equivalent to a full-time pharmacist salary lost annually to retroactive PBM clawbacks. The 2024 CMS rule change moved DIR to point-of-sale but did not eliminate the underlying clawback economics.
Compounding pharmacy penetration averages 5.6% nationally
Approximately 855 compounding pharmacies operate across US states, representing 5.6% of the total 15,278 registered pharmacies in states with compounding data. Compounding penetration varies dramatically by state — from 15.1% in Oklahoma (US leader) to under 3% in some Northeast and Great Plains states. Compounding niches (503A patient-specific formulations, HRT, veterinary, weight-loss injectables) generate 40-60% margins compared to 8-12% on commodity generics.
Cash-pay prescription volume grew 22% YoY in 2024
US cash-pay prescription volume reached an estimated $32B in 2024, growing 20-25% annually. Cash-pay share of total US retail prescription revenue is now approximately 11% — projected to reach 18-22% by 2028. Drivers: 52% of employer-sponsored insurance is high-deductible in 2024, Medicare Part D coverage gap persistence, PBM formulary exclusions on high-demand medications (GLP-1 weight-loss), and Amazon Pharmacy $5 flat-price generic tier.
Amazon Pharmacy captured 4-6% US retail Rx market share by 2025
Amazon Pharmacy (built on the 2018 PillPack acquisition) captured 4-6% of US retail prescription market share by end of 2025. The $5 flat-price generic tier — often below independent wholesale acquisition cost — is subsidised by Prime membership economics. Amazon Pharmacy revenue grew ~40% YoY in 2024. Highest exposure: high-volume generic dispensers. Lowest exposure: specialty + compounding pharmacies (Amazon does not compound).
CVS Caremark charges 6.8% median DIR — highest of Big Three PBMs
CVS Caremark is the largest PBM by market share (~35%) and historically charges the highest DIR rates on Medicare Part D. Median 2024 rates: Caremark 6.8%, Express Scripts 5.9%, OptumRx 4.7%, Regional PBMs 4.2%. Star rating multiplies these rates: 5-star pharmacies pay 40% less, 1-star pharmacies pay 30% more. On a 200-Rx/day pharmacy with 45% Medicare Part D volume: Caremark exposure alone typically exceeds $85K annually.
42 of 51 US states have PBM transparency laws — federal reform stalled
47 of 51 US states + DC have enacted PBM transparency + regulation laws as of Q1 2026, up from 28 in 2020. Strongest regulation: Arkansas (Act 900 + Rutledge v. PCMA 2020 SCOTUS ruling), Kentucky (AG recovered $10.4M from Express Scripts 2024), Ohio (AG recovered $16M from OptumRx). Federal PBM reform (H.R. 2870 Pharmacy Benefit Manager Reform Act) passed House 2024 but stalled in Senate. State-level patchwork continues — federal relief unlikely before 2028.
17 active federal + state lawsuits against Big Three PBMs
Independent pharmacy consortiums, state attorneys general, and pharmacy industry associations have 17 active lawsuits against CVS Caremark, Express Scripts, and OptumRx as of 2026. Active AG actions: Texas (multi-PBM anti-competitive investigation), Louisiana (Caremark discriminatory practices), California (statewide DIR/GER/MAC investigation). Private class actions: NCPA + independent plaintiffs vs Caremark (certification 2026), independent consortium vs ESI (discovery 2025). Rite Aid bankruptcy proceedings include PBM contract dispute settlements in progress.
72% of US independents are in PSAOs — solo pharmacies pay 20-25% more in DIR
Approximately 72% of US independent pharmacies participate in a Pharmacy Services Administrative Organization (AmerisourceBergen Elevate, Cardinal Health LEADER, or McKesson Health Mart Atlas). PSAO members receive 15-25% DIR fee reductions on average vs solo-negotiating independents, plus better wholesale contract terms, MAC appeal services, and GER dispute support. Solo independents pay significantly more in structural PBM disadvantages — a 200-Rx/day solo pharmacy typically leaves $30K-$50K/year on the table vs PSAO membership.
Pharmacies at 25%+ cash-pay revenue are 3.2× more likely to be profitable
NCPA 2024 profitability study data: independent pharmacies with 25% or more of revenue from cash-pay patients are 3.2× more likely to report positive net margin vs pure PBM-dependent independents. Cash-pay revenue has zero DIR fee exposure, no MAC squeeze, no PBM clawback risk. Median independent cash-pay share is 8-12%; top quartile is 20-30%. The gap between median and top quartile is the single largest predictor of independent pharmacy survival probability over 3-year horizons.
US pharmacy market split: 30% independents, 40% chains, 15% mail-order, 15% specialty
By retail prescription volume, the US pharmacy market splits approximately: 30% independent community pharmacies, 40% chain pharmacies (CVS 22%, Walgreens 15%, Rite Aid + others 3%), 15% mail-order + Amazon Pharmacy, 15% specialty pharmacies. Chain share has been contracting (CVS -900 stores 2022-2024, Walgreens -1,200+, Rite Aid Chapter 11) but the closures represent 4-8% of chain footprint vs 20-30% attrition for independents over the same period. Chains are contracting; independents are decimating.
GLP-1 compounding is a $2-4B/year opportunity through at least 2027
Compounded semaglutide + tirzepatide represents the largest current specialty pharmacy opportunity. 503A patient-specific compounding for weight-loss + diabetes indications generates 40-60% margins vs 8-12% on commodity generics. Regulatory risk: Novo Nordisk and Eli Lilly have both pursued patent enforcement actions against compounders, but compounding within 503A patient-specific criteria (individualised formulation, allergy documentation, dose combinations not commercially available) remains legally protected. GLP-1 compounding penetration is heavily concentrated in Oklahoma, Texas, Utah, Kansas, and Nebraska — leading compounding states.
Top 15 US States by Pharmacy Count
These 15 states account for the majority of US pharmacy volume. Compounding penetration varies dramatically — Oklahoma leads at 15.1%, followed by Utah at 13.7%.
| State | Pharmacies | Compounders | Compound % | Uninsured |
|---|---|---|---|---|
| California | 8,905 | 463 | 5.2% | 7% |
| New York | 8,628 | 336 | 3.9% | 5.2% |
| Texas | 7,618 | 610 | 8.0% | 18.4% |
| Florida | 7,195 | 454 | 6.3% | 13.2% |
| Pennsylvania | 3,728 | 148 | 4.0% | 5.9% |
| Michigan | 3,658 | 215 | 5.9% | 5.4% |
| North Carolina | 3,371 | 151 | 4.5% | 10.4% |
| New Jersey | 3,247 | 149 | 4.6% | 7.4% |
| Ohio | 3,172 | 131 | 4.1% | 7.2% |
| Illinois | 2,930 | 100 | 3.4% | 7.4% |
| Georgia | 2,773 | 156 | 5.6% | 12.4% |
| Tennessee | 2,028 | 150 | 7.4% | 10.5% |
| Washington | 1,903 | 91 | 4.8% | 6.5% |
| Virginia | 1,849 | 101 | 5.5% | 7.7% |
| Maryland | 1,781 | 92 | 5.2% | 6.4% |
Source: NPI federal registry (Feb 2026 snapshot). Compounding penetration = compounding pharmacies as % of total registered pharmacies.
Top 10 States by Compounding Penetration
Compounding pharmacy density is heavily concentrated in a handful of states. These 10 states have compounding penetration above the US average of 5.6%.
5 Strategic Recommendations
Based on the 12 findings above, these 5 strategic priorities have the strongest evidence base for improving independent pharmacy financial outcomes in 2026-2028.
Diversify to 25%+ cash-pay revenue within 18 months
Cash-pay revenue is the only stream with zero PBM exposure. Independents at 25%+ cash-pay are 3.2× more likely to be profitable. Fastest path: join a cash-pay marketplace ($149/mo per location) + establish local visibility. Payback period typically 4-8 months.
Calculate your recovery mathAchieve 4+ star rating on major PBM networks
Star rating improvement from 3 to 4 stars typically saves $30K-$50K annually on a 200-Rx/day pharmacy via reduced DIR rates. Highest-leverage improvement: medication synchronization + adherence packaging (blister packs, Sync Rx, PrescribeWellness). Timeline: 6-12 months to move stars 0.5-1 point.
PBM clawback deep-diveAdd or expand a specialty niche (compounding, POCT, MTM)
503A compounding, point-of-care testing + immunizations, and medication therapy management (MTM) billing generate 3-5× commodity generic margins. GLP-1 compounding is the biggest current specialty opportunity at 40-60% margins.
Revenue diversification playbookJoin a PSAO if not already member
PSAO membership (Elevate, LEADER, Atlas) delivers 15-25% average DIR reduction, better MAC appeal support, and collective PBM contract negotiation. Solo independents leave $30K-$50K/year on the table vs PSAO members. Payback period: <2 months.
PSAO comparison guideModernise patient acquisition — cash-pay marketplaces + local SEO
Pharmacies with active online presence acquire cash-pay patients 5-8× faster than passive pharmacies. Combine cash-pay marketplace membership + Google Business Profile optimization + patient reviews + local content SEO. Amazon Pharmacy is beatable on service + convenience + specialty — never on commodity price alone.
Amazon defensive strategyScript Unlock — The Cash-Pay Recovery Platform
Script Unlock is the cash-pay prescription marketplace independents use to execute Recommendation #01 (25%+ cash-pay diversification). Verified pharmacies compete for cash-paying patients — every fill is 100% PBM-free revenue with zero DIR, GER, or MAC exposure.
Pharmacies on Script Unlock typically move 15-30% of Rx volume to cash-pay within 6 months. On a 200-Rx/day pharmacy with typical $150K-$200K annual DIR exposure, moving 25% of volume to cash-pay recovers approximately $75K-$120K/year in DIR-free revenue — 50-80× the $149/month subscription cost.
$149/month per location · No long-term contract · Free trial available
Deep-Dive Reports
This executive report references extensive supporting analysis in individual topic reports. Follow the links below to explore specific issue areas in depth.
Methodology + Data Sources
Pharmacy counts: Aggregated from NPI federal registry (National Plan and Provider Enumeration System) February 2026 snapshot. Includes all pharmacies with active pharmacy taxonomy codes.
Compounding pharmacies: Filtered by NPI taxonomy codes 3336C0003X (Community/Retail Compounding) and 3336C0004X (Compounding Pharmacy).
Independent pharmacy estimates: Rough estimate calculated as total pharmacies minus known chain pharmacy counts per state. Actual figures vary — for precise state-level data, consult individual state pharmacy board records.
Financial data (DIR fees, revenue, profitability): NCPA 2024 State of Independent Pharmacy report + NCPA Digest supplemental studies.
Cash-pay market data: IQVIA 2024 Institute reports, Kaiser Family Foundation Employer Health Benefits Surveys.
PBM data: Company public filings (CVS Health, UnitedHealth Group, Cigna Corporation), Drug Channels Institute analysis, NCPA member surveys.
State PBM regulation: NABP state legislative tracker Q1 2026, state attorney general press releases, state pharmacy board websites. Regulatory data current as of Q1 2026 and subject to legislative session changes — verify with your state pharmacy board before making legal decisions.
Legal actions: NCPA legal tracker, state AG press releases, federal court dockets, PACER filings for private class actions.
Not legal, accounting, or business advice. This report provides directional market intelligence for strategic planning. Consult qualified advisors before making specific decisions. Some statistics are estimates or extrapolations from limited public data — annotated where relevant.
Editorial: This report was compiled by the Script Unlock Pharmacy Verification Team. Script Unlock operates a cash-pay prescription marketplace for independent pharmacies and has a commercial interest in cash-pay marketplace adoption. Data presented is sourced from independent third-party research (NCPA, IQVIA, KFF, state government) rather than Script Unlock proprietary data. Where recommendations reference Script Unlock, this is clearly identified.
Citation
To cite this report:
Free to cite and share with attribution. No login required.
Report No. 2026-SU-01 · Published 2026-07-12 · By Script Unlock Pharmacy Verification Team
Data sources: NCPA 2024 Digest, NPI federal registry, NABP legislative tracker, IQVIA 2024, KFF, state AG press releases·Verified pharmacy standards